Abstract:Abstract Development of an electrochemical diagnostic test would provide quantitative detection of biomarkers characteristic of clinical serum samples that may facilitate early detection and triage of glioma patients in the clinical setting. Today, 32 individuals will receive a confirmatory diagnosis of a brain tumor in the UK, equivalent to 3% of all patients diagnosed with cancer annually. Implications for patients and families are tragic, brain cancer is responsible for >5,000 mortalities annually in the UK, with 20.1 mean years of life lost to the disease per patient, greater than any other cancer. Presently, ~22% of brain cancer patients receive diagnosis through GP referral, with over a third of patients attending their health practice on five occasions prior to diagnosis. Brain tumor symptoms are diverse and often non-specific in the absence of epileptic seizures, with an extremely poor positive predictive value. Consequently, suspected patients experience significant diagnostic delays, with significant time spent in primary care settings. Heightened symptoms often translates to emergency presentation, where >60% of brain cancer patients currently receive diagnosis, associated with reduced survival compared to non-emergency pathways. Hence, earlier detection of brain cancer patients is a clinical need within primary care settings to prevent significant diagnostic delays and improve patient outcomes. Introduction of a widespread screening program with medical imaging modalities is not economically viable for early detection of brain cancer given high test costs and low incidence in the general population. However, a recent health economic study suggested a blood-based test may prove cost saving to NHS services if employed to triage brain tumor patients for medical imaging in primary and secondary care. Blood is fundamental to physiological function of cells and their perpetual interaction provides a rich source of endogenous molecules that may reflect biochemical events of gliomagenesis. Our current work towards development of a blood-based electrochemical platform for brain cancer focuses on screening of clinical serum samples for a large panel of cytokines from confirmed patients with glioma tumor types. Thereafter, our work demonstrates electrochemical detection of elevated cytokine biomarkers identified within our serum samples. Previously, we demonstrated the potential of this platform technology for early detection of Hodgkin lymphoma, with successful discrimination between cancerous and non-cancerous patient samples, which we now hope to extend to early detection of brain cancer. Implementation of a low-cost, point-of-care triage blood test for brain cancer would have significant clinical and economical benefits, ultimately facilitating the promotion of early detection strategies in primary care to enable timely cancer diagnosis and improve patient outcomes. Citation Format: Christopher Rinaldi, Ashton G. Theakstone, Damion Corrigan, Paul Brennan, Matthew J. Baker. Towards an electrochemical serum-based platform for early diagnosis and stratification of glioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2598.

Early detection of multiple myeloma: A first step towards a screening programme

Laboratory practice is central to earlier myeloma diagnosis: Utilizing a primary care diagnostic tool and laboratory guidelines integrated into haematology services

Laboratory reflex testing strategy for the early identification of primary care patients with multiple myeloma

Proactive consultation of laboratory medicine increased diagnostic rate of multiple myeloma: One single center's 12-year experience

Employment of Artificial Intelligence Based on Routine Laboratory Results for the Early Diagnosis of Multiple Myeloma

Screening in Multiple Myeloma and Its Precursors: Are We There Yet?

Routine blood biomarkers for the detection of multiple myeloma using machine learning

A multi-cancer early detection (MCED) test: clinical update for GPs

Automated Early Detection of Myelodysplastic Syndrome within the General Population Using the Research Parameters of Beckman–Coulter DxH 800 Hematology Analyzer

Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples

Transforming the landscape of early cancer detection using blood tests—Commentary on current methodologies and future prospects

A novel early cancer detection approach for pancreatic cancer.

Clinical performance and utility: A microsimulation model to inform the design of screening trials for a multi-cancer early detection test

Shifting the Cancer Screening Paradigm: Developing a Multi-Biomarker Class Approach to Multi-Cancer Early Detection Testing

Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice Paper

Correlation analysis of laboratory indicators, genetic abnormalities and staging in patients with newly diagnosed multiple myeloma

The Impact on Early Diagnosis and Survival Outcome of M-protein Screening-Driven Diagnostic Approach to Multiple Myeloma in China: a Cohort Study

Leukaemia diagnosis and primary care

Abstract 2598: Towards an electrochemical serum-based platform for early diagnosis and stratification of glioma

Cancer: Government backs multiple blood tests as part of {pound}11m early diagnosis push

B-307 Comparative studies on serum quantitative immunoglobulin assay and serum protein electrophoresis for the diagnosis of multiple myeloma